Arm FY2025 valuation: strong growth, thin free cash flow and a high P/E

That makes scenario analysis more useful than a single headline DCF value.

First, define the period: FY2025 is not calendar Q4 2025

Arm’s relevant period here is fiscal year 2025, not the fourth quarter of the 2025 calendar year. Twelve Data lists Arm’s fiscal year end and most recent quarter as March 31, 2025. Arm’s investor presentation uses the “Q4 FYE25” label and reports total revenue of $1.241 billion for that fiscal fourth quarter, up 34% year over year.

So in this analysis, “Q4 FYE25” means the fiscal quarter ended March 31, 2025.

Key FY2025 and TTM numbers

Growth is strong, but one year is not a five-year CAGR

The cleanest growth comparison in the available data is FY2024 to FY2025. USFINIQ lists FY2024 revenue at $3.233 billion and FY2025 revenue at $4.007 billion, which implies about 23.9% year-over-year growth; the same source describes FY2025 revenue growth as 24.1%.

USFINIQ also lists FY2025 net income at $792 million versus $306 million in FY2024, and describes net income growth as 159.8%. That supports the view that Arm’s recent growth has been strong.

But it does not support a precise five-year CAGR. The provided sources do not include a complete five-year sequence for revenue, EPS, net income and free cash flow. For a valuation model, that matters: a one-year growth rate should not be used as a substitute for a full long-term growth record.

Peer comparisons also need care. CSIMarket says Arm’s revenue grew 23.94% in the fourth quarter of 2025 and that semiconductor industry revenue grew 26.21%; Arm’s own investor presentation says Q4 FYE25 total revenue grew 34% year over year. Those figures may reflect different period definitions or data conventions, so they should not be turned into a sweeping long-term industry conclusion.

Free cash flow is the main swing factor

StockTitan lists Arm’s free cash flow at $178 million, well below FY2025 revenue of $4.007 billion. As a rough cross-check, that puts free cash flow at about 4.4% of revenue.

The same StockTitan data list operating cash flow at $397 million, capital spending at $219 million and receivables rising to $1.1 billion. That points to cash conversion as a key issue for valuation.

This does not necessarily mean Arm’s long-term cash generation has deteriorated. Arm’s investor presentation says FYE25 trailing-twelve-month free cash flow was negatively affected by the reversal of a Q4 FYE24 working-capital benefit related to awards vesting after the IPO.

Still, for a high-multiple stock, investors need more than revenue growth. They need evidence that revenue and accounting profit can turn into repeatable free cash flow.

The P/E is already pricing in a lot

Twelve Data lists Arm’s trailing P/E at 192.96x, forward P/E at 70.25x and price-to-sales ratio at 38.26x. CSIMarket also says Arm’s current trailing-twelve-month P/E is above the semiconductor industry average, although the provided excerpt does not give the industry-average P/E number.

That supports a cautious conclusion: Arm is a high-expectation stock. But without a complete peer table for P/E, PEG, margins and growth rates, it would be misleading to invent a competitor average.

The practical implication is simple: if earnings or free cash flow fall short, the valuation has less room for disappointment.

WACC: use scenarios, not false precision

A precise WACC calculation normally requires beta, cost of equity, after-tax cost of debt, tax assumptions and a full capital structure. The provided sources do not supply all of those inputs. A better approach is to build sensitivity cases around the discount rate, revenue growth and terminal growth rate.

These are DCF modelling inputs, not Arm guidance and not market consensus. If the model is highly sensitive to terminal value, the first things to check are whether the terminal growth rate is too high and whether the free cash flow margin assumption is too optimistic.

A practical base-case revenue path

For a neutral model, it is more reasonable to fade growth over time than to assume FY2025 or Q4 FYE25 growth continues forever. FY2025 revenue was about $4.007 billion, while Q4 FYE25 revenue was $1.241 billion and up 34% year over year.

What should not be treated as precisely known

• Cash and short-term investments: Twelve Data verifies total cash MRQ of $2.82 billion, but the provided sources do not break out short-term investments.
• Total liabilities or total debt: USFINIQ lists net debt at negative $1.729 billion, which indicates a net cash position under its methodology, but net debt is not the same as total liabilities or a detailed debt schedule.
• Five-year CAGR: The provided data do not include a full five-year financial sequence, so FY2025’s one-year growth rate should not be used as a five-year CAGR.
• Industry and peer averages: The sources provide limited quarterly and valuation context, and the CSIMarket growth figure does not line up exactly with Arm’s Q4 FYE25 investor-presentation figure.
• FY2025 revenue growth rate: The same FY2025 revenue figure of $4.007 billion appears alongside different growth descriptions: 20.6% in Architecting IT and roughly 24% in USFINIQ’s data and text.

Bottom line

Arm’s FY2025 numbers support the view that the business is growing quickly: FY2025 revenue was about $4.007 billion, net income was about $792 million, and Q4 FYE25 revenue reached $1.241 billion, up 34% year over year.

But the stock’s valuation is demanding. Twelve Data lists a trailing P/E of 192.96x and a forward P/E of 70.25x, while StockTitan lists free cash flow at $178 million.

A balanced valuation framework would start with a neutral DCF case: WACC of 10%–11%, five-year revenue CAGR of 15%–20%, and terminal growth of 3.0%–3.5%. If free cash flow fails to scale with revenue and net income, the model should use a higher discount rate or lower terminal value. If cash conversion improves meaningfully, then a more optimistic growth-and-WACC combination becomes easier to test.